Beryl Drugs, a company in the Pharmaceuticals industry, reported revenue of ₹6.93 crore and net profit of ₹0.06 crore for the September 2026 quarter.
Beryl Drugs (BSE: BERLDRG) closed at ₹24.70 on 20 Nov 2026, up 8.6% over the past year. Its market capitalisation is ₹13 crore and it trades at 18.7 times earnings.
Incorporated in 1993, Beryl Drugs Ltd is in the business of pharmaceuticals manufacturing
Descriptive research only, not investment advice. Evenstocks is not a SEBI-registered investment adviser.